Skip to main content
. Author manuscript; available in PMC: 2019 Nov 26.
Published in final edited form as: Pharmacol Res. 2019 Feb 7;142:267–282. doi: 10.1016/j.phrs.2019.02.002

Fig. 10.

Fig. 10.

URB937 has no effect on cell line viability in HEK293 cells in the presence or absence of paclitaxel. Dose-response curve for the effect of (A) paclitaxel and (B) URB937 in HEK293 cells. Abs EC50, Absolute EC50 > 500 nM, reflects no inhibition of HEK293 cell viability by paclitaxel at the highest concentration tested; Abs EC50, Absolute EC50 > 100 μM, reflects little or no inhibition of HEK293 cell viability by URB937 at the highest concentration tested. (C, D) Single-agent and combination responses determined by an MTT viability assay in HEK293 cells. (C) Paclitaxel dose response shift observed in the presence of increasing concentrations of URB937. (D) URB937 dose response shift observed in the presence of increasing concentrations of paclitaxel. (E–G) The 3-dimensional landscape of the dose matrix is represented on a color scale, where blue reflects evidence of synergy and red reflects evidence of antagonism. The landscape of the dose matrix combination responses for URB937 and paclitaxel based on the (E) Bliss model, (F) Highest Single Agent (HSA) model and (G) Loewe model. Cell viability is plotted as % control (n = 3 experiments).